29 February 2012

Statins tied to diabetes, memory risks

US health regulators will add warnings to the labels of widely used statins, saying they may raise levels of blood sugar and could cause memory loss.


US health regulators will add warnings to the labels of widely used cholesterol lowering drugs, saying they may raise levels of blood sugar and could cause memory loss.

The Food and Drug Administration announced the changes to the safety information on the labels of statins that are taken by tens of millions of people. The FDA said the new information should not scare people away from taking the drugs.

"The value of statins in preventing heart disease has been clearly established," Amy Egan, deputy director for safety in FDA's Division of Metabolism and Endocrinology Products, said. "Their benefit is indisputable, but they need to be taken with care and knowledge of their side effects."

Statins and heart disease

Lipitor (atorvastatin), which became available late, last year in generic form, is the world's all-time biggest selling prescription medicine with cumulative sales in excess of R980 billion. As a class, statins have helped enrich the world's largest drug makers, but most of the major brands are now prescribed as far cheaper generic medicines.

Last year, more than 20 million Americans were taking some form of statin, according to IMS Health.

"These are nuances, tiny little tweaks to the label, and the bigger picture doesn't change," said Dr Steven Nissen, chief of cardiology at Cleveland Clinic. "There are few drugs that have saved as many lives as statins and we don't want to throw the baby out with the bath water here.

"If you have heart disease, you probably should be on a statin. If you're at high risk, a statin may be warranted. But we don't think these drugs should be put in the water supply," Dr Nissen said.

Statins increase risk of high blood pressure

One safety warning long associated with the class of medicines will be reversed, the FDA said. Patients taking statins will no longer need periodic monitoring of liver enzymes, since cases of serious liver injury are rare and unpredictable in individual patients.

Asked what prompted the label changes, FDA spokeswoman Erica Jefferson said they were based on the agency's review of medical literature, clinical trial data and reports of adverse events.

"I wouldn't point to any one thing," she said. "We've been looking at all the information for some time. It's part of our ongoing surveillance."

The FDA has said it was aware of studies in which some patients taking statins may have a small increased risk of higher blood sugar levels and of being diagnosed with type 2 diabetes.

Don’t take statins with HIV drugs

The statin labels will also now reflect reports of certain cognitive effects such as memory loss and confusion experienced by some patients taking the drugs, the agency said. It said those reports generally have not been serious and the symptoms were reversed by stopping use of the statin.

"We have known for three or four years that statins slightly increase blood sugar," Dr Nissen said. "The fact that the blood sugar went up a little bit did not diminish the effectiveness of the statins in reducing (heart) risk for patients."

The FDA also specifically said that Merck's Mevacor, the world's first approved statin, known generically as lovastatin, should never be taken with certain drugs used to treat HIV and certain bacterial and fungal infections due to increased risk of a serious muscle disease.

"I don't think we should change our practise based on this report," said Dr Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Centre in New York.

"But the report is a sobering reminder there's no such thing as a free lunch," Dr Ong said. Every drug has its problems and its side effects, despite the benefits."

(Bill Berkrot and Ransdell Pierson, Reuters Health, February 2012) 

Read more:

Statins reduce heart disease risk

Type 2 diabetes



Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.